4547 キッセイ薬品工業

時価

1607億円

PER 予

12.75倍

2010年以降

7.23-53.23倍
（2010-2024年）

0.65倍

2010年以降

0.43-1.25倍
（2010-2024年）

2.76%

ROE 予

5.14%

ROA 予

4.33%

営業外費用計、小計、Accounts Payable Other他6件

【期間】

年度	営業外費用計	小計	Accounts Payable Other	法人税等合計	Impairment LossEL - Pharmaceutical Products Member	Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member	Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member	Deferred Tax LiabilitiesNCL	親会社株主に係る四半期包括利益
2009/12	262百万	59.5億	-	22.3億	-	-	-	-	-
2010/12	236百万 -9.9%	26.6億 -55.2%	-	20.2億 -9.1%	-	-	-	-	13億
2011/12	142百万 -39.8%	40.5億 +52.1%	-	28.2億 +39.3%	-	-	-	-	29.5億 +127%
2012/12	42百万 -70.4%	-	-	27.8億 -1.5%	-	-	-	-	59.4億 +101.2%
2013/12	40百万 -4.8%	-	-	41.9億 +50.9%	-	-	-	-	108億 +81.8%
2014/12	28百万 -30%	-	-	32.3億 -22.8%	-	-	-	-	116億 +7.7%
2015/12	28百万 ±0%	-	-	33.8億 +4.5%	-	-	-	-	140億 +20%
2016/12	105百万 +275%	-	-	24億 -29%	-	-	-	-	41.4億 -70.4%
2017/12	77百万 -26.7%	-	-	24.5億 +2.2%	-	-	-	-	211億 +409.9%
2018/12	396百万 +414.3%	-	-	12.9億 -47.3%	-	-	-	-	-3.5億赤転
2019/12	60百万 -84.8%	-	-	12億 -7.2%	-	-	-	-	140億黒転
2020/12	55百万 -8.3%	-	-	20.8億 +73.5%	-	-	-	-	241億 +71.7%
2021/12	101百万 +83.6%	-	-	18.1億 -13%	-	-	-	-	-154億赤転
2022/12	52百万 -48.5%	-	-	22.5億 +24.1%	-	-	-	-	-24.2億赤縮
2023/12	131百万 +151.9%	-	-	26.5億 +17.9%	-	-	-	-	116億黒転

2009年12月

営業外費用計: 2億6200万
小計: 59億4800万
Accounts Payable Other: -
法人税等合計: 22億2500万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: -

2010年12月

営業外費用計: 2億3600万
小計: 26億6400万
Accounts Payable Other: -
法人税等合計: 20億2300万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 13億100万

2011年12月

営業外費用計: 1億4200万
小計: 40億5100万
Accounts Payable Other: -
法人税等合計: 28億1900万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 29億5300万

2012年12月

営業外費用計: 4200万
小計: -
Accounts Payable Other: -
法人税等合計: 27億7700万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 59億4000万

2013年12月

営業外費用計: 4000万
小計: -
Accounts Payable Other: -
法人税等合計: 41億9000万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 107億9800万

2014年12月

営業外費用計: 2800万
小計: -
Accounts Payable Other: -
法人税等合計: 32億3300万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 116億2900万

2015年12月

営業外費用計: 2800万
小計: -
Accounts Payable Other: -
法人税等合計: 33億8000万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 139億5100万

2016年12月

営業外費用計: 1億500万
小計: -
Accounts Payable Other: -
法人税等合計: 24億
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 41億3500万

2017年12月

営業外費用計: 7700万
小計: -
Accounts Payable Other: -
法人税等合計: 24億5300万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 210億8600万

2018年12月

営業外費用計: 3億9600万
小計: -
Accounts Payable Other: -
法人税等合計: 12億9200万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: -3億5000万

2019年12月

営業外費用計: 6000万
小計: -
Accounts Payable Other: -
法人税等合計: 11億9900万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 140億3500万

2020年12月

営業外費用計: 5500万
小計: -
Accounts Payable Other: -
法人税等合計: 20億8000万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 240億9200万

2021年12月

営業外費用計: 1億100万
小計: -
Accounts Payable Other: -
法人税等合計: 18億1000万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: -153億5600万

2022年12月

営業外費用計: 5200万
小計: -
Accounts Payable Other: -
法人税等合計: 22億4600万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: -24億2200万

2023年12月

営業外費用計: 1億3100万
小計: -
Accounts Payable Other: -
法人税等合計: 26億4800万
Impairment LossEL - Pharmaceutical Products Member: -
Number Of Employees - Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activities Member: -
Capital Expenditures Overview Of Capital Expenditures Etc - Trading Business Reportable Segment Member: -
Deferred Tax LiabilitiesNCL: -
親会社株主に係る四半期包括利益: 115億7000万